Beutel Goodman & Co Ltd. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 244,289 shares of the company’s stock after purchasing an additional 4,656 shares during the period. Beutel Goodman & Co Ltd.’s holdings in Johnson & Johnson were worth $22,552,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Partners grew its holdings in Johnson & Johnson by 68.7% during the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after acquiring an additional 5,207,124 shares during the period. DDD Partners LLC grew its holdings in Johnson & Johnson by 2.1% during the first quarter. DDD Partners LLC now owns 65,984 shares of the company’s stock worth $8,456,000 after acquiring an additional 1,381 shares during the period. Tradition Capital Management LLC grew its holdings in Johnson & Johnson by 1.9% during the first quarter. Tradition Capital Management LLC now owns 41,550 shares of the company’s stock worth $5,324,000 after acquiring an additional 759 shares during the period. Flossbach Von Storch AG grew its holdings in Johnson & Johnson by 100.1% during the first quarter. Flossbach Von Storch AG now owns 2,318,450 shares of the company’s stock worth $297,109,000 after acquiring an additional 1,159,690 shares during the period. Finally, Miles Capital Inc. grew its holdings in Johnson & Johnson by 8.0% during the first quarter. Miles Capital Inc. now owns 12,430 shares of the company’s stock worth $1,593,000 after acquiring an additional 923 shares during the period. Institutional investors own 66.60% of the company’s stock.
JNJ has been the topic of several research analyst reports. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a report on Friday, September 14th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $142.54.
In other news, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The disclosure for this sale can be found here. Company insiders own 0.22% of the company’s stock.
NYSE JNJ opened at $142.20 on Tuesday. The company has a market capitalization of $377.43 billion, a PE ratio of 19.48, a PEG ratio of 2.20 and a beta of 0.58. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.32. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.90 earnings per share. On average, research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
WARNING: “Beutel Goodman & Co Ltd. Has $22.55 Million Holdings in Johnson & Johnson (JNJ)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/06/beutel-goodman-co-ltd-has-22-55-million-holdings-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Swap
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.